Leukemia Research
Volume 28, Issue 8 , Pages 813-819 , August 2004

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group

  • William R Friedenberg

      Affiliations

    • Hematology/Oncology, Guthrie Clinic, One Guthrie Square, Sayre, PA 18840, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-570-882-2141; fax: +1-570-882-2010.
    • ,
  • Martin S Tallman

      Affiliations

    • Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University Medical School, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA
    • Tel.: 1-312-695-6180; fax: 1-312-695-6189.
    • ,
  • Isadore Brodsky

      Affiliations

    • Drexel University College of Medicine, Broad & Vine Street MS412, Philadelphia, PA 19102, USA
    • Tel.: 1-215-762-7026; fax: 1-215-762-8857.
    • ,
  • Elisabeth Paietta

      Affiliations

    • Our Lady of Mercy Medical Center, 600 E 233rd Street 6th Fl, Bronx, NY 10466-2604, USA
    • Tel.: 1-718-920-9992; fax: 1-718-920-1161.
    • ,
  • Jacob M Rowe

      Affiliations

    • Rambam Medical Center and Technion, Bat Galim, 31096 Haifa, Israel
    • Tel.: 972-4-854-2541; fax: 972-4-854-2343.
    • ,
  • Sandra J Lee

      Affiliations

    • Department of Biostatistical Science, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    • ,
  • Kendrith M Rowland Jr.

      Affiliations

    • Carle Clinic Assoc., 812 W University Ave, Champaign, IL 61820-3922, USA
    • Tel.: 1-217-383-3010; fax: 1-217-383-3466.
    • ,
  • George W Schnetzer

      Affiliations

    • 2111 E 26th Street, Tulsa, OK 74114, USA
    • Tel.: 1-918-743-8004.
    • ,
  • John C Reed

      Affiliations

    • The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    • Tel.: 1-858-646-3132; fax: 1-858-646-3184.

Received 8 September 2003 ,Accepted 2 December 2003.

References 

  1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Eng. J. Med. 1995;16:1052–1057
  2. Friedenberg WR, Spencer SK, Musser C, Hogan TF, Rodvold KA, Rushing DA, et al.  Multidrug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma. 1999;34(1–2):171–178
  3. Bradley G, Guranka PF, Ling V. Mechanisms of multidrug resistance. Biochim. Biophys. Acta. 1988;948:87–128
  4. Dalton WS, Grogan TM. Does p-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? J Natl Cancer Inst 1991;83:80–1.
  5. Dalton WS, Grogan TM, Durie BGM, et al.  Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989;7:415–424
  6. Dalton WS, Grogan TM, Rybski JA, et al.  Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood. 1989;73:747–752
  7. Silber R, Potmesil M, Ban BB. Studies on drug resistance in chronic lymphocytic leukemia. Adv. Enzyme Reg. 1989;29:267–276
  8. Cumber PM, Jacobs A, Hoy T, Fisher J, Whittaker JA, Tsuruo T, et al.  Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia. Br. J. Haematol. 1990;76:226–230
  9. Shustik C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br. J. Haematol. 1991;79:50–56
  10. Sonneveld P, Nooter K, Burghouts JTM, Herweijer H, Adriaansen HJ, van Dongen JJM. High expression of the MDR, mutltidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood. 1992;79:1496–1500
  11. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, et al.  P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993;82:3452–3459
  12. Holmes JA, Jacobs A, Carter G, Whittaker JA, Bentley DP, Padua RA. Is the MDR1 gene relevant in chronic lymphocytic leukemia?. Leukemia. 1990;4:216–218
  13. Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C, Michelutti A, et al.  The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1991;77:460–465
  14. Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, et al.  Activity of p-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst. 1993;85:1751–1758
  15. Sparrow RL, Hall FJ, Siregar H, Van Der Weyden MB. Common expression of the multidrug resistance marker p-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk. Res. 1993;17:941–947
  16. Friedenberg WR, Andersen J, Wolf BC, Cassileth PA, Oken MM. Modified vincristine, doxorubicin, and dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic leukemia. Cancer. 1993;71:2983–2989
  17. Sonneveld P, Durie GB, Lokhorst HM, Marie JP, Solbu G, Suciu S, et al.  Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet. 1992;340:255–259
  18. List AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology. 1993;7:23–38
  19. Friedenberg WR, Hogan TF, Rodvold KA, Rushing DA, Tewksbury DA, Spencer S, et al.  Multidrug resistance (MDR) in chronic lymphocytic leukemia (CLL). Proc. ASCO. 1994;13:309; (abstract 1013)
  20. Friedenberg WR, Musser C, Spencer S, Mercier R, Clouse L, Mazza JJ, et al.  Multidrug resistance (MDR) in chronic lymphocytic leukemia (CLL). Proc. ASCO. 1995;14:179; (abstract 400)
  21. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel nonimmunosuppressive cyclosporine-A. Eur. J. Cancer. 1991;27:1639–1642
  22. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of p-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Res. 1991;51:4226–4233
  23. Giaccone G, Linn SC, Catimel G, Dumortier A, Foy M, Vermorken JB, et al.  SDZ PSC-833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors. Anticancer Drugs. 1994;5(Suppl 1):42
  24. Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J. A phase I trial of doxorubicin (DOX) and PSC-833, a modulator of multidrug resistance (MDR). Anticancer Drugs. 1994;5(Suppl 1):42
  25. Case Jr DC, Jain V, Stiff P, Jansen J, Stewart AK, Shurafa M, et al. Phase II study of PSC 833 (PSC) and VAD chemotherapy in patients with VAD-refractory multiple myeloma (MM). Therapy of Chronic lymphocytic Leukemia and Multiple Myeloma. Abstract 427. Poster Board #/Session: 427-I, p. 105a.
  26. Dalton W, Greipp P, Greenberg P, Stiff P, Ballester O, Friedenberg W, et al.  Phase I study of the chemosensitizer SDZ PSC-833 in combination with VAD chemotherapy to reverse multidrug resistance. Blood. 1996;88(Suppl 1):662a
  27. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJF, et al.  A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC-833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 1997;3:2005–2015
  28. Cheson BD, Bennett JM, Grever M, et al.  National Cancer Institute Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  29. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, et al.  Significantly lower p-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 1994;8:968–973
  30. Paietta E, Andersen J, Racevskis J, Ashigbi M, Cassileth P, Wiernik PH. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Blood Rev. 1995;9:47–52
  31. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. J. Article Multicenter Study Blood. 1998;91(9):3379–3389
  32. American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471–508.
  33. Simon R. Optimal two-stage designs for phase II clinical studies. Control. Clin. Trials. 1989;10:1–10
  34. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982;5:649–655
  35. Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 1958;53:457–481
  36. List AF, Ikopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group Study. Clinical observations, interventions, and therapeutic trials. Blood. 2001;98:3212–3219
  37. Baer et al. Phase 3 Study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 15 August 2002;100:1225–32.
  38. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, et al.  Phase II study of paclitaxel and valspodar (PSC-833) in refractory ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2001;19:2975–2993
  39. Friedenberg WR, Salzman SA, Phan SM, Burmester JK. Transforming growth factor-β and multidrug resistance in chronic lymphocytic leukemia. Med. Oncol. 1999;16:110–118

PII: S0145-2126(03)00414-4

doi: 10.1016/j.leukres.2003.12.002

Leukemia Research
Volume 28, Issue 8 , Pages 813-819 , August 2004

Article Tools